FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385198350> ?p ?o ?g. }

• W4385198350 abstract "Ustekinumab (UST) optimization strategies, including shortening intervals and intravenous reinduction, should be administered to patients with partial or loss of respond. Evidence comparing these types of optimization treatments is limited. We evaluated the efficacy and safety of weight-based UST intravenous reinduction in patients with refractory Crohn's disease (CD).This was a single-center retrospective observational study. Optimization strategies were designed for patients showing partial or loss of response to standardized UST therapy. Clinical, biochemical, and endoscopic response and remission rate were determined by Crohn's disease activity index (CDAI), C-reactive protein (CRP) levels, and SES-CD evaluation. UST trough concentrations were detected and adverse events were recorded.A total of 128 patients receiving UST optimization therapies were included, with 105 patients administered shortening intervals of q8w or q4w, and 23 receiving intravenous reinduction followed by subcutaneous q8w or q4w. The follow-up duration for the shortening interval and reinduction cohorts were 15.0 (10.0, 31.0) and 23.0 (13.0, 70.0) weeks, respectively. A significant CDAI delta variation pre-and post-treatment could be found between groups [17.0 (-4.4, 65.9) vs. 69.0(10.7, 151.0), p = 0.013]. the trough concentration of UST increased [2.5 (1.3, 5.3) vs. 1.1 (0.5, 2.3), p = 0.001] after intravenous reinduction. Clinical and endoscopic remission were achieved in 69.6 and 31.8% of patients in the intravenous reinduction cohort, and 62.9 and 22.2% of patients in the shortening interval cohort, respectively. No significant difference was found between groups regarding safety.Intravenous reinduction brought about favorable recapture of clinical and endoscopic remission, and should have significant priority over the strategy of merely shortening drug intervals, which should be launched before switching to other biologics targeting different inflammatory pathways.Clinical Trial Registration: identifier NCT04923100. https://classic.clinicaltrials.gov/ct2/show/NCT04923100?id=04923100&draw=2&rank=1." @default.
• W4385198350 created "2023-07-25" @default.
• W4385198350 creator A5004485941 @default.
• W4385198350 creator A5005522695 @default.
• W4385198350 creator A5008398838 @default.
• W4385198350 creator A5011869476 @default.
• W4385198350 creator A5016128638 @default.
• W4385198350 creator A5031503063 @default.
• W4385198350 creator A5043155714 @default.
• W4385198350 creator A5046597133 @default.
• W4385198350 creator A5050269387 @default.
• W4385198350 creator A5053204257 @default.
• W4385198350 creator A5092530540 @default.
• W4385198350 date "2023-07-24" @default.
• W4385198350 modified "2023-10-18" @default.
• W4385198350 title "Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease" @default.
• W4385198350 cites W1752248076 @default.
• W4385198350 cites W1981526671 @default.
• W4385198350 cites W2071662837 @default.
• W4385198350 cites W2077531651 @default.
• W4385198350 cites W2085127303 @default.
• W4385198350 cites W2102013054 @default.
• W4385198350 cites W2342091014 @default.
• W4385198350 cites W2464681208 @default.
• W4385198350 cites W2523706394 @default.
• W4385198350 cites W2548168877 @default.
• W4385198350 cites W2597769394 @default.
• W4385198350 cites W2603226668 @default.
• W4385198350 cites W2786974934 @default.
• W4385198350 cites W2922074884 @default.
• W4385198350 cites W2936468435 @default.
• W4385198350 cites W2948759662 @default.
• W4385198350 cites W2950457069 @default.
• W4385198350 cites W3008210779 @default.
• W4385198350 cites W3026001080 @default.
• W4385198350 cites W3036375450 @default.
• W4385198350 cites W3126382441 @default.
• W4385198350 cites W3126842225 @default.
• W4385198350 cites W3132666517 @default.
• W4385198350 cites W3157971178 @default.
• W4385198350 cites W3205367234 @default.
• W4385198350 cites W3205711768 @default.
• W4385198350 cites W4210985415 @default.
• W4385198350 cites W4224218616 @default.
• W4385198350 cites W4226370828 @default.
• W4385198350 cites W4226491388 @default.
• W4385198350 cites W4233817719 @default.
• W4385198350 cites W4280617602 @default.
• W4385198350 cites W4289518741 @default.
• W4385198350 cites W4296623163 @default.
• W4385198350 cites W4297257214 @default.
• W4385198350 cites W4300817321 @default.
• W4385198350 cites W4302276593 @default.
• W4385198350 cites W4307097434 @default.
• W4385198350 doi "https://doi.org/10.3389/fmed.2023.1105981" @default.
• W4385198350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37554510" @default.
• W4385198350 hasPublicationYear "2023" @default.
• W4385198350 type Work @default.
• W4385198350 citedByCount "0" @default.
• W4385198350 crossrefType "journal-article" @default.
• W4385198350 hasAuthorship W4385198350A5004485941 @default.
• W4385198350 hasAuthorship W4385198350A5005522695 @default.
• W4385198350 hasAuthorship W4385198350A5008398838 @default.
• W4385198350 hasAuthorship W4385198350A5011869476 @default.
• W4385198350 hasAuthorship W4385198350A5016128638 @default.
• W4385198350 hasAuthorship W4385198350A5031503063 @default.
• W4385198350 hasAuthorship W4385198350A5043155714 @default.
• W4385198350 hasAuthorship W4385198350A5046597133 @default.
• W4385198350 hasAuthorship W4385198350A5050269387 @default.
• W4385198350 hasAuthorship W4385198350A5053204257 @default.
• W4385198350 hasAuthorship W4385198350A5092530540 @default.
• W4385198350 hasBestOaLocation W43851983501 @default.
• W4385198350 hasConcept C121332964 @default.
• W4385198350 hasConcept C126322002 @default.
• W4385198350 hasConcept C142424586 @default.
• W4385198350 hasConcept C167135981 @default.
• W4385198350 hasConcept C197934379 @default.
• W4385198350 hasConcept C2777138892 @default.
• W4385198350 hasConcept C2778975655 @default.
• W4385198350 hasConcept C2779134260 @default.
• W4385198350 hasConcept C2779280984 @default.
• W4385198350 hasConcept C2909675724 @default.
• W4385198350 hasConcept C2911091166 @default.
• W4385198350 hasConcept C31785415 @default.
• W4385198350 hasConcept C71924100 @default.
• W4385198350 hasConcept C72563966 @default.
• W4385198350 hasConcept C87355193 @default.
• W4385198350 hasConcept C90924648 @default.
• W4385198350 hasConceptScore W4385198350C121332964 @default.
• W4385198350 hasConceptScore W4385198350C126322002 @default.
• W4385198350 hasConceptScore W4385198350C142424586 @default.
• W4385198350 hasConceptScore W4385198350C167135981 @default.
• W4385198350 hasConceptScore W4385198350C197934379 @default.
• W4385198350 hasConceptScore W4385198350C2777138892 @default.
• W4385198350 hasConceptScore W4385198350C2778975655 @default.
• W4385198350 hasConceptScore W4385198350C2779134260 @default.
• W4385198350 hasConceptScore W4385198350C2779280984 @default.
• W4385198350 hasConceptScore W4385198350C2909675724 @default.
• W4385198350 hasConceptScore W4385198350C2911091166 @default.
• W4385198350 hasConceptScore W4385198350C31785415 @default.

• next